Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Kath Kerry

Summer Intern experience at Research Partnership

We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research

Inizio

- PMLiVE

NICE backs use of AZ’s Brilique as maintenance therapy

Drug to be used with asprin as treatment for heart attack patients

- PMLiVE

Health Unlimited forms partnership with HealthUnlocked

Aims to drive organic and new business for the agency and social network

Health Unlimited announces partnership with HealthUnlocked to expand direct-to-consumer insight and engagement

London, 12th August 2016. Health Unlimited, the specialist healthcare marketing communications group, part of Creston Unlimited, today announces a global partnership agreement with HealthUnlocked.

Health Unlimited

- PMLiVE

Patient reporting rises after EU pharmacovigilance reforms

Safety issues detected more quickly with increased patient participation

- PMLiVE

EMD Serono president James Hoyes joins consultants RxC

Takes up a role as executive partner at the US management consulting firm

- PMLiVE

Multichannel: the essential European revolution

Boosting the digital component in Europe's multichannel engagement strategy

Eli Lilly HQ

Lilly presses on with breast cancer study despite setback

CDK 4/6 inhibitor abemaciclib shows disappointing results in phase III trial

- PMLiVE

Germany’s IQWIG ‘perplexed’ by EMA’s adaptive pathways plan

Reliance on real-world evidence questioned

- PMLiVE

Dr Robert Kim joins Apellis as chief medical officer

Brings experience from Novartis, Genentech and GSK

- PMLiVE

Managing value: Why early asset development and commercialisation are important

Realising the full value of your asset - clinically and commercially - means thinking beyond the pure scientific value, even at the very early stages of development

- PMLiVE

NICE turns down CDF drug Adcetris in draft guidance

Takeda’s treatment for Hodgkin’s lymphoma not seen to be cost-effective

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links